-1 One Report) for the year 2021 (3) the reviewed financial statements for Q1/2022 (4) the reviewed financial statements for Q2/2022 (5) the reviewed financial statements for Q3/2022 to the SEC within
transmission system of the Stock Exchange of Thailand within the period specified in the notification as follows : (1) the reviewed financial statements for Q1/2022, (2) the reviewed financial statements for Q2
prepare and submit (1) the reviewed financial statements for Q1/2022, (2) the reviewed financial statements for Q2/2022 and (3) the reviewed financial statements for Q3/2022 through the transmission system
size is 0.55%. Please refer to the financial statements of the Company. And its subsidiaries as at September 30, 2018. This is considered as the transaction size of asset acquisition.The size of the
business growth, while decreasing -0.5% QoQ from higher SG&A. EBITDA margin improved to 54% from continual focus in profitable revenue, cost management, and improved device margin. AIS reported a net profit
their services to all customers. The Company, leading distributor of medical device, is developing new products; medical software, together with plan to shift from distributor to manufacture to serve
product quality (the company has been awarded ISO 13485, the Quality Management System for Medical Device Industry), which is an important tool in the competition and expansion of the market in the future